Phenotypic correction and stable expression of factor VIII in hemophilia A mice by embryonic stem cell therapy

Genetics and Molecular Research

Volumn 12, Issue 2, 2013, Pages 1511-1521

  Wang, J J ^a   Kuang, Y ^b   Zhang, L L ^c   Shen, C L ^c   Wang, L ^d   Lu, S Y ^d   Lu, X B ^b   Fei, J ^b   Gu, M M ^a   Wang, Z G ^a,d  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b Shanghai Research Center for Model Organisms   (China)

^c INSTITUTE OF GEOLOGY AND GEOPHYSICS   (China)

^d SHANGHAI SECOND MEDICAL UNIVERSITY   (China)

Author keywords

Blastocysts; Chimeric mice; Embryonic stem cells; FVIII; Hemophilia A

Indexed keywords

BLOOD CLOTTING FACTOR 8; GREEN FLUORESCENT PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLASTOCYST; BLOOD CLOTTING; EMBRYONIC STEM CELL; FEMALE; HEMOPHILIA A; MALE; MOUSE; NONHUMAN; PHENOTYPE; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION; STEM CELL TRANSPLANTATION;

EID: 84878065369     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.May.13.4     Document Type: Article

References (32)

1. Balague C, Zhou J, Dai Y, Alemany R, et al. (2000). Sustained high-level expression of full-length human factor VIII and restoration of clotting activity in hemophilic mice using a minimal adenovirus vector. Blood 95: 820-828.
2. Doetschman T, Maeda N and Smithies O (1988). Targeted mutation of the Hprt gene in mouse embryonic stem cells. Proc. Natl. Acad. Sci. U. S. A. 85: 8583-8587.
3. Fakharzadeh SS, Zhang Y, Sarkar R and Kazazian HH Jr (2000). Correction of the coagulation defect in hemophilia A mice through factor VIII expression in skin. Blood 95: 2799-2805.
4. Guo X, Wang H, Chu H, Wang X, et al. (2001). High level expression of human factor VIII in mammalian cells after retroviral-mediated gene transfer. Chin. Med. J. 114: 690-693.
5. Hanna J, Wernig M, Markoulaki S, Sun CW, et al. (2007). Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 318: 1920-1923.
6. Hauck B, Xu RR, Xie J, Wu W, et al. (2006). Efficient AAV1-AAV2 hybrid vector for gene therapy of hemophilia. Hum. Gene Ther. 17: 46-54.
7. Hoots WK and Nugent DJ (2006). Evidence for the benefits of prophylaxis in the management of hemophilia A. Thromb. Haemost. 96: 433-440.
8. Hwang WS, Ryu YJ, Park JH, Park ES, et al. (2004). Evidence of a pluripotent human embryonic stem cell line derived from a cloned blastocyst. Science 303: 1669-1674.
9. Ide LM, Gangadharan B, Chiang KY, Doering CB, et al. (2007). Hematopoietic stem-cell gene therapy of hemophilia A incorporating a porcine factor VIII transgene and nonmyeloablative conditioning regimens. Blood 110: 2855-2863.
10. Kaufman RJ (1999). Advances toward gene therapy for hemophilia at the millennium. Hum. Gene Ther. 10: 2091-2107.
11. Kessler CM (2005). New perspectives in hemophilia treatment. Hematology Am. Soc. Hematol. Educ. Program 429-435.
12. Kootstra NA, Matsumura R and Verma IM (2003). Efficient production of human FVIII in hemophilic mice using lentiviral vectors. Mol. Ther. 7: 623-631.
13. Kuang Y, Wang J, Lu X, Lu S, et al. (2010). Generation of factor VIII gene knockout mouse by tetraploid embryo complementation technology. Zhonghua Yi. Xue. Yi. Chuan Xue. Za Zhi. 27: 1-6.
14. Lewitzky M and Yamanaka S (2007). Reprogramming somatic cells towards pluripotency by defined factors. Curr. Opin. Biotechnol. 18: 467-473.
15. Matsui H, Shibata M, Brown B, Labelle A, et al. (2007). Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem. Cells 25: 2660-2669.
16. Mintz B and Silvers WK (1967). Intrinsic:immunological tolerance in allophenic mice. Science 158: 1484-1486.
17. Moayeri M, Hawley TS and Hawley RG (2005). Correction of murine hemophilia A by hematopoietic stem cell gene therapy. Mol. Ther. 12: 1034-1042.
18. Montgomery RR, Monahan PE and Ozelo MC (2010). Unique strategies for therapeutic gene transfer in haemophilia A and haemophilia BWFH State-of-the-Art Session on Therapeutic Gene Transfer Buenos Aires, Argentina. Haemophilia (Suppl 16) 5: 29-34.
19. Okita K, Ichisaka T and Yamanaka S (2007). Generation of germline-competent induced pluripotent stem cells. Nature 448: 313-317.
20. Park IH, Zhao R, West JA, Yabuuchi A, et al. (2008). Reprogramming of human somatic cells to pluripotency with defined factors. Nature 451: 141-146.
21. Pierce GF, Lillicrap D, Pipe SW and Vandendriessche T (2007). Gene therapy, bioengineered clotting factors and novel technologies for hemophilia treatment. J. Thromb. Haemost. 5: 901-906.
22. Robertson EJ, Evans MJ and Kaufman MH (1983). X-chromosome instability in pluripotential stem cell lines derived from parthenogenetic embryos. J. Embryol. Exp. Morphol. 74: 297-309.
23. Saenko EL, Ananyeva NM, Moayeri M, Ramezani A, et al. (2003). Development of improved factor VIII molecules and new gene transfer approaches for hemophilia A. Curr. Gene Ther. 3: 27-41.
24. Scandella DH (2000). Properties of anti-factor VIII inhibitor antibodies in hemophilia A patients. Semin. Thromb. Hemost. 26: 137-142.
25. Takahashi K, Tanabe K, Ohnuki M, Narita M, et al. (2007). Induction of pluripotent stem cells from adult human fibroblasts by defined factors. Cell 131: 861-872.
26. Tiede A, Eder M, von Depka M, Battmer K, et al. (2003). Recombinant factor VIII expression in hematopoietic cells following lentiviral transduction. Gene Ther. 10: 1917-1925.
27. Xu D, Alipio Z, Fink LM, Adcock DM, et al. (2009). Phenotypic correction of murine hemophilia A using an iPS cellbased therapy. Proc. Natl. Acad. Sci. U. S. A. 106: 808-813.
28. Xu L, Nichols TC, Sarkar R, McCorquodale S, et al. (2005). Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy. Proc. Natl. Acad. Sci. U. S. A. 102: 6080-6085.
29. Xu L, Mei M, Ma X and Ponder KP (2007). High expression reduces an antibody response after neonatal gene therapy with B domain-deleted human factor VIII in mice. J. Thromb. Haemost. 5: 1805-1812.
30. Yatuv R, Robinson M, Dayan-Tarshish I and Baru M (2010). The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia. Int. J. Nanomedicine 5: 581-591.
31. Ye P, Thompson AR, Sarkar R, Shen Z, et al. (2004). Naked DNA transfer of Factor VIII induced transgene-specific, species-independent immune response in hemophilia A mice. Mol. Ther. 10: 117-126.
32. Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, et al. (2007). Induced pluripotent stem cell lines derived from human somatic cells. Science 318: 1917-1920.